MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Open-label, single-group Phase 2 pilot assessing feasibility and tolerability of manualised MDMA-assisted therapy in 10 dyads (20 participants) of cancer patients and concerned significant others over an 8-week treatment period.

Intervention comprises two MDMA dosing sessions (100 mg with optional 40 mg supplemental dose), two preparatory therapy sessions, and four integration sessions; outcomes include feasibility, tolerability, and preliminary effectiveness measures.